Peptides Could Change Concussion Care, So Let’s Get It Right

, , , ,

I get the same question from athletes, parents, and fighters: Can peptides help the brain heal after a concussion? Here’s my answer.


Walk through any training facility in 2026, and you will hear the same three letters: BPC. Players trade peptide stories in the locker room. Podcasters swear by them. Influencers sell “research peptides” with a wink and a disclaimer. And more and more,

I have spent more than 20 years in sports medicine, including time as an NFL team physician, and much of my career working on concussion protocols across football, MMA, and basketball.

My honest answer is this: science is genuinely exciting, and the job now is to prove it in athletes the right way.

What We’re Actually Talking About

Peptide therapy (graphic courtesy of SeeBeyond Medicine)

Peptides are short chains of amino acids, the same building blocks that make up proteins. Your body makes thousands of them. Medicine already uses many approved peptide drugs, and they are rigorously studied and regulated.

But that is not what most athletes mean when they say “peptides.” They mean a handful of compounds that live in a gray zone. The most famous is BPC-157, short for “body protection compound,” a fragment first studied for stomach ulcers and gut healing. Next is TB-500, a synthetic fragment of thymosin beta-4 that athletes use for soft-tissue recovery. Others with names like Semax and Selank are pitched for focus, mood, and “brain health.”

Where these compounds stand with the FDA, including what can be compounded and what can’t, seems to change by the day, sometimes by the hour. To be completely and utterly transparent, I won’t try to pin that down here, because anything I write today could be outdated by the time you read it. Your provider is the best source for where things stand right now.

Why Concussion Doctors Are Paying Attention

A concussion is not just the hit. It is what happens over the hours and days after: inflammation, oxidative stress, disrupted blood flow, swelling, and cells struggling to restore their energy balance.

Once that cascade starts, we have almost nothing that directly protects the injured brain. We manage symptoms, we use graded return-to-play, and we wait.

In the lab, peptides have shown that they can interfere with that cascade. A 2010 mouse study of BPC-157 found less bleeding, less brain swelling, and better early outcomes after a falling-weight brain injury. Researchers at Hebrew University reported that a single dose of experimental “thioredoxin-mimetic” peptides, given an hour after a mild brain injury in mice, protected memory and learning at 7 and 30 days. A small peptide called CAQK targets injured brain tissue and reduces damage in mice and pigs.

The strongest human data comes from a different compound. Cerebrolysin, a peptide mixture derived from pig brain proteins, has been tested in randomized, double-masked, placebo-controlled trials. A 2021 meta-analysis of the CAPTAIN trials reported benefit in 185 patients. But those were hospitalized patients with moderate-to-severe brain injuries, not a linebacker who got his bell rung on Sunday, and Cerebrolysin is not approved in the United States.

Notice the pattern. Mice. Rats. Pigs. Hospital patients with severe injuries. What we do not have is a well-designed human trial showing that any of these peptides improve recovery from a sports concussion. Not one.

Two Real Risks for Athletes

The first is anti-doping. The World Anti-Doping Agency has banned BPC-157 at all times, in and out of competition, since 2022, under its category for non-approved substances. A test for it exists. Olympic athletes, UFC fighters under anti-doping programs, and NCAA athletes are all exposed.

Whatever the FDA decides, a positive test can still end a season or a career. The second is quality. Most athletes don’t get peptides from a licensed pharmacy. They are buying vials labeled “not for human consumption” from websites with no oversight. You do not know the dose, the purity, or whether the vial even contains what the label says. Injecting an unknown substance to help an injured brain is the opposite of good medicine.

Where Do We Go from Here?

I am pro-peptide. I am also anti-guessing. If any of these compounds can calm the inflammatory storm after a head injury, I want them in the medical tent, not in a gym bag. The way to get there is the same way we have got real concussion protocols: by doing the work.

So, here is what I would like to see. The leagues, the players’ associations, and the NIH should fund real human trials in athletes that measure what matters: symptoms, return-to-play time, balance, cognition, and blood biomarkers. Sports already have most trials only dream of baseline testing on every player. Team physicians should ask every concussed athlete about peptide use, without judgment, because you cannot manage what you don’t know about.

Just as important is who is doing the talking. Peptides shouldn’t be peddled by the guy at the gym or sold through an influencer’s discount code. Some of those influencers are extremely well-read on the research, and they deserve credit for starting this conversation. But knowing the literature is not the same as being qualified to make patient decisions.

If you are interested in peptides, talk to your provider. Provider-only supply chains sell to licensed clinicians, not consumers. And 503A compounding pharmacies can now prepare a limited number of peptides for individual patients with a prescription.

The right path is simple: a provider, a prescription, and a pharmacy that meets regulatory requirements.

Peptides could become one of the most important tools we have in brain injury medicine. The animal data is compelling, the need is real, and athletes are already asking.

Now let’s give them the science and the safe path they deserve.

_______________

Dr. Brian “Bones” Allard, DC, has more than 20 years in sports medicine. He is a former NFL team physician and is an active contributor and professional consultant to the ongoing development of concussion protocols across all sports.

Sources

Tudor M, et al. Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. Regulatory Peptides, 2010.

Hebrew University. Novel peptide protects cognitive function after mild traumatic brain injury (Baratz-Goldstein R et al., PLoS One, 2016).

NR Times. Peptide shows significant neuroprotective effect for TBI (CAQK).

Vester JC, et al. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurological Sciences, 2021.

WADA. 2025 Prohibited List, S0 Non-Approved Substances; 2022 Prohibited List naming BPC-157.



Leave a Reply

Your email address will not be published. Required fields are marked *